ISRG - Intuitive Surgical, Inc. Stock Analysis

DATE	TYPE	RATIO
2021-10-05	Forward	3:1
2017-10-06	Forward	3:1
2003-07-01	Reverse	1:2

DATE

TYPE

RATIO

2021-10-05

Forward

3:1

2017-10-06

Forward

3:1

2003-07-01

Reverse

1:2

Latest News

ZACKS INVESTMENT RESEARCH · OCT 7, 2026

Can ISRG's Single-Port Platform Become the Next Billion-Dollar Franchise?

Intuitive Surgical SP platform is gaining momentum as procedures, utilization and placements rise, with expanding indications and global adoption fueling growth.

READ ARTICLE

EARLIER COVERAGE

247 WALLST · OCT 7, 2026

Here Are Wednesday’s Top Wall Street Analyst Research Calls: Abbott Laboratories, AppFolio, Delek US Holdings, Flutter Entertainment, Honeywell Aerospace, Intuitive Surgical, Marvell, NetApp, and More

Stocks shattered records again Tuesday while oil surged, gold hit new highs, and crypto swung wildly, setting the stage for a fresh wave of analyst moves on names like Marvell, Intuitive Surgical, and NetApp that could reshape portfolios heading into the rest of the week.

READ ARTICLE

ZACKS INVESTMENT RESEARCH · OCT 6, 2026

Zacks Industry Outlook Globus Medical, Intuitive Surgical and Thermo Fisher Scientific

Globus Medical, Intuitive Surgical and Thermo Fisher Scientific have been highlighted in this Industry Outlook article.

READ ARTICLE

SEEKING ALPHA · OCT 6, 2026

Intuitive Surgical: The Multiple Fell, The Story Didn't

Intuitive Surgical remains a wide-moat leader in robotic surgery with strong secular tailwinds and high recurring revenue potential. ISRG's installed base and utilization rates offer significant runway for growth, supported by product innovation and expansion into new markets. Despite a compression in valuation multiples, ISRG's forward P/E remains attractive given its historical premium and robust growth prospects.

READ ARTICLE

ZACKS INVESTMENT RESEARCH · OCT 5, 2026

3 Medical Instruments Stocks Using GenAI to Navigate Industry Woes

GenAI offers growth opportunities for GMED, ISRG and TMO, but evolving regulations and industry risks are likely to shape adoption.

READ ARTICLE

FOOL - INVESTING NEWS · OCT 5, 2026

2 Beaten-Down Stocks Worth Buying and Holding for the Next Decade

These companies haven't said their last words.

READ ARTICLE

SEEKING ALPHA · OCT 2, 2026

Intuitive Surgical: The 17% Selloff Is A Buy

Intuitive Surgical, Inc. remains a Buy, with strong recurring revenue, robust cash generation, and a market-leading position in robotic surgery despite recent share price weakness. Q3 expectations reflect slower procedure growth and affordability pressures, but ISRG's installed base, da Vinci 5 upgrade cycle, and SP/Ion adoption underpin long-term growth. Margins are expected to peak this year, aided by extended use programs that lower system costs and potentially increase competitive barriers.

READ ARTICLE

ZACKS INVESTMENT RESEARCH · OCT 2, 2026

Can ISRG Offset China Weakness With Expansion in India and Japan?

Intuitive Surgical sees strong growth in India and improving conditions in Japan helping offset China headwinds as international da Vinci procedures rise 20%.

READ ARTICLE

THE MOTLEY FOOL · OCT 1, 2026

Abbott Laboratories vs. Intuitive Surgical: Which Healthcare Stock Is a Better Buy in 2026?

Abbott Laboratories offers a highly diversified revenue stream across medical devices, diagnostics, and nutrition. Intuitive Surgical maintains a dominant lead in robotic-assisted surgery with high recurring revenue from instruments and services.

READ ARTICLE

THE MOTLEY FOOL · OCT 1, 2026

Is Wall Street Dead Wrong About Intuitive Surgical? Here's My Honest Answer.

Twenty-four of 32 analysts covering Intuitive Surgical rate the stock as a "buy" or "strong buy." However, Intuitive faces multiple headwinds that are pressuring its growth.

READ ARTICLE

SHOWING 2–10 OF 12